Chronic Cough Market Forecasts to 2030 – Global Analysis By Drug Class (Antibiotics, Acid Blockers, Corticosteroids, Decongestants, Combination Drug, Antihistamines and Other Drug Classes), Route of Administration, Distribution Channel, End User and By Ge

Chronic Cough Market Forecasts to 2030 – Global Analysis By Drug Class (Antibiotics, Acid Blockers, Corticosteroids, Decongestants, Combination Drug, Antihistamines and Other Drug Classes), Route of Administration, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Chronic Cough Market is accounted for $7.3 billion in 2023 and is expected to reach $14.3 billion by 2030 growing at a CAGR of 10.0% during the forecast period. A chronic cough is a persistent cough that lasts for more than eight weeks in adults or four weeks in children, according to most medical definitions. It's a symptom rather than a disease itself and can be caused by a variety of underlying conditions such as asthma, allergies, gastroesophageal reflux disease (GERD), postnasal drip, smoking, chronic bronchitis, or certain medications. Chronic cough can significantly impact quality of life and may require medical evaluation to determine the underlying cause and appropriate treatment.

According to the National Health Policy 2017, India, premature mortality due to non-communicable diseases, including chronic cough, will be reduced by ~ 25% by 2025.

Market Dynamics:

Driver:

Increasing prevalence of chronic respiratory diseases

The market is witnessing a notable rise in chronic respiratory diseases prevalence. This surge is attributed to various factors such as environmental pollution, lifestyle changes, and aging populations. Chronic respiratory conditions are increasingly prevalent, contributing to the expansion of the market. With growing awareness and diagnostic advancements, the demand for effective treatments for chronic respiratory ailments continues to escalate, driving further growth in this sector.

Restraint:

Side effects and safety concerns

Common side effects of pharmaceutical treatments for chronic cough include drowsiness, dizziness, and gastrointestinal disturbances. There are safety concerns regarding potential drug interactions and the risk of dependency or abuse with certain medications. Patients with underlying medical conditions such as cardiovascular issues or respiratory disorders may face heightened risks. It's imperative for healthcare providers to carefully assess each patient's medical history and closely monitor treatment outcomes to mitigate these concerns. Hence, these are the factors impeding the growth of the market.

Opportunity:

Rising healthcare expenditure

The market is witnessing a notable surge in healthcare expenditure, driven by various factors such as increased diagnosis rates, expanding patient populations, and advancements in treatment options. As awareness grows and more patients seek medical attention for chronic cough, healthcare spending continues to rise steadily. This trend underscores the significance of addressing chronic cough as a healthcare priority and highlights the need for continued investment in research, development, and patient care initiatives within this market segment.

Threat:

High cost of treatment

The market grapples with the significant challenge of high treatment costs, posing a considerable burden on patients and healthcare systems alike. The expenses associated with therapies and ongoing management contribute to financial strain for individuals seeking relief from this persistent condition. Despite advancements in medical technology and treatment modalities, the steep costs remain a barrier to access for many, underscoring the pressing need for affordable and sustainable solutions within the healthcare landscape.

Covid-19 Impact:

The COVID-19 pandemic significantly affected the Chronic Cough market, causing disruptions in diagnosis, treatment, and patient care. Lockdown measures, reduced healthcare access, and prioritization of resources towards managing COVID-19 led to delays in chronic cough management. Additionally, fear of visiting healthcare facilities deterred patients from seeking timely treatment. Consequently, there was a decline in diagnosis rates and treatment initiation, impacting market growth. Telemedicine emerged as a preferred mode for consultation, offering some relief amidst restrictions but couldn't fully compensate for in-person evaluations.

The decongestants segment is expected to be the largest during the forecast period

The decongestants segment is expected to be the largest during the forecast period driven by increasing awareness and prevalence of respiratory conditions. They alleviate nasal congestion and postnasal drip, addressing underlying causes of persistent coughing. Pharmaceutical companies actively engage in research and development to enhance existing formulations and introduce novel decongestant products. This dynamic market landscape underscores the importance of effective decongestants in managing chronic cough and related respiratory ailments.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. Leading hospitals specializing in respiratory health, such as renowned academic medical centers and pulmonology departments, are crucial players. These hospitals offer comprehensive services, including diagnostic imaging, pulmonary function testing, and access to multidisciplinary teams of specialists. Additionally, they provide cutting-edge therapies and clinical trials, ensuring patients receive optimal care and management for their chronic cough conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Pharmaceutical interventions, including antitussive medications and targeted therapies, dominate the market landscape. Additionally, a surge in research and development activities aimed at novel treatment modalities further propels market expansion. With a focus on improving patient outcomes and quality of life, the market continues to evolve with promising opportunities for innovation and investment.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to increasing pollution levels, rising geriatric population, changing lifestyles leading to higher incidence of respiratory diseases, and growing awareness about available treatment options. Additionally, there was growing interest in non-pharmacological interventions such as speech therapy, breathing exercises, and lifestyle modifications. Regulatory frameworks governing the market varied across countries in the region, influencing market dynamics and product availability.

Key players in the market

Some of the key players in Chronic Cough market include Teva Pharmaceuticals Industries, Mylan N.V., Amneal Pharmaceuticals LLC, Novartis AG, Hikma Pharmaceuticals Plc, Bayer AG, GSK plc, Aurobindo Pharma, Apotex Inc., Micro Labs Ltd, AstraZeneca plc, Sun Pharmaceuticals Industries Ltd, Cipla Limited, Glenmark Pharmaceuticals Ltd, NeRRe Therapeutics and Pfizer Inc.

Key Developments:

In September 2022, Pfizer Inc., a US-based biopharmaceutical company, acquired ASX-listed digital health startup ResApp Health for $115 million. With this acquisition, Pfizer aimed to enhance its product portfolio and expand its presence in crucial healthcare technology areas.

In January 2022, Merck announced Gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of patients with RCC or unexplained chronic cough (UCC), was approved by FDA.

Drug Classes Covered:
• Antibiotics
• Acid Blockers
• Corticosteroids
• Decongestants
• Combination Drug
• Antihistamines
• Other Drug Classes

Route of Administrations Covered:
• Inhalational
• Oral
• Injectable
• Other Route of Administrations

Distribution Channels Covered:
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

End Users Covered:
• Speciality Centres
• Homecare
• Hospitals
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements